• Home/
  • Industry/
  • Listing/
  • Participants/
  • Public Release Docs/
  • Omalizumab/
  • Omalizumab

Omalizumab: 24 month predicted versus actual analysis

Drug utilisation sub-committee (DUSC)

June 2014

Full report on Omalizumab: 24 month predicted versus actual analysis (PDF 813KB)

Full report on Omalizumab: 24 month predicted versus actual analysis (Word 429KB)

Abstract

Purpose

To examine the utilisation of omalizumab in the 24 months after listing (1 July 2011 to 30 June 2013).

Background

The 12 month predicted versus actual (PvA) analysis presented at the February 2013 DUSC meeting showed lower than predicted use.  The DUSC requested a second analysis of omalizumab once 24 months of data was available.

Data Source / methodology

The Authority Approvals Database was used for the majority of analyses.  The Highly Specialised Drugs Database was used to analyse the quantity of vials supplied and cost to Government. The Supplied Prescriptions Database was used for a small number of analyses.

Key Findings

The utilisation of omalizumab over the first 24 months of listing was lower than estimated.

  • 258 patients received an authority approval for omalizumab in the second year of listing, including 156 new patients.  This is fewer total and new patients than predicted.
  • Over 80% of patients who received an initial authority approval received a continuing authority approval.
  • An average 3.76 vials was approved per prescription over the first two years of listing, which was approximately 20% more than predicted.